Methods for treating lysosomal acid lipase deficiency in patients
AssigneeAlexion Pharmaceuticals, Inc.
InventorAnthony Quinn
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of treating LAL deficiency comprising administering to a mammal a therapeutically effective amount of lysosomal acid lipase with an effective dosage frequency. Methods of improving growth and liver function, increasing LAL tissue concentration, and increasing LAL activity in a human patient suffering from LAL deficiency are also provided.
Claims7
A method of treating a human infant suffering from a lysosomal acid lipase (LAL) deficiency comprising administering to the infant 1 milligram (mg), 3 mg, or 5 mg of recombinant human LAL per kilogram (kg) body weight.
A method of treating a human subject suffering from a lysosomal acid lipase (LAL) deficiency, wherein the subject is a child or an adult, comprising administering to the subject 1 mg/kg or 3 mg/kg of recombinant human LAL.
A method of treating a human subject suffering from a lysosomal acid lipase (LAL) deficiency, comprising administering to the subject 1 mg/kg, 3 mg/kg, or 5 mg/kg of recombinant human LAL over a period of 1 to 8 hours by intravenous infusion.
A method of treating a human subject suffering from a lysosomal acid lipase (LAL) deficiency, comprising:
- a) administering an antihistamine to the subject;
- and
- b) after administration of the antihistamine, administering 1 mg/kg or 5 mg/kg of recombinant human LAL to the subject.
Dependencies are inferred from the claim text.